The Bispecific Antibody Therapeutics Contract Manufacturing Market Size is valued at US$ 5.39 Bn in 2022 and is predicted to reach US$ 82.85 Bn by the year 2031 at an 35.6% CAGR during the forecast period for 2023-2031.
Bispecific antibodies are highly preferred in therapeutic approaches. These antibody therapeutics provide many therapeutic benefits and help meet the patient's unmet needs. In addition, the therapeutic potential to treat cancer, diabetes, Alzheimer's, and ophthalmological diseases drive the market demand. Great interest and investment in bispecific antibodies are essential to business growth.
Furthermore, growing research in drug discovery, rising clinical trials for antibody therapeutics, high cancer burden worldwide, surging demand for advanced therapeutics, and increasing R&D activities to develop novel therapies are anticipated to produce lucrative growth opportunities in this market over the coming years.
Competitive Landscape:
Some of the Key Players in the Bispecific Antibody Therapeutics Contract Manufacturing Market:
- Lonza
- Roche's
- Creative Biolabs
- AbbVie
- Amgen
- Janssen
- Johnson & Johnson
- IQVIA
- WuXi Biologicsb b
- Sino Biological Inc.
- Other Prominent Players
Market Segmentation:
The Bispecific Antibody Therapeutics Contract Manufacturing Market is segmented based on indication, route of administration, and end-users. The indication segment comprises cancer, infectious diseases, autoinflammatory and autoimmune diseases, and CNS conditions. The market is classified into intravenous, subcutaneous, and others by route of administration. End-users categorize the market into pharmaceutical companies, biopharmaceutical companies, and others.
Cancer Is Expected To Drive The Bispecific Antibody Therapeutics Contract Manufacturing Market In The Upcoming Years
By indication, the cancer segment accounted for the most increased revenue share in 2022. The increased demand for bispecific antibody therapeutics and rising cancer cases globally drive this segment. Similarly, due to its safety and efficacy profile, the bispecific antibody therapeutics contract manufacturing market has become an attractive choice for treating cancer.
The Intravenous Segment Is Growing At The Highest Rate In The Bispecific Antibody Therapeutics Contract Manufacturing Market
Based on the route of administration, the intravenous segment recorded the largest revenue share in 2022. Intravenous antibodies have many advantages in cancer recovery. These antibody therapeutics via IV help the immune system to fight and kill cancer cells more effectively.
Biopharmaceutical Companies Dominated The Market In 2022
By end-users, the biopharmaceutical companies segment dominated the bispecific antibody therapeutics contract manufacturing market in 2022. The increasing demand for advanced antibody therapies, the high prevalence of cancer, and growing R&D investments are responsible for driving the growth of the biopharmaceutical companies and market.
Regionally, North America Led The Bispecific Antibody Therapeutics Contract Manufacturing Market In 2022
North America Bispecific Antibody Therapeutics Contract Manufacturing Market dominated in 2022 and is estimated to continue its trend over 2023-2031. Characteristics such as the growing demand for innovative antibody therapies, increased prevalence of cancer, increasing mergers and acquisitions among companies, rising R&D activities, increasing government investments for clinical research and the growing number of clinical trials contribute to the market growth.
Bispecific Antibody Therapeutics Contract Manufacturing Market Report Scope:
Report Attribute |
Specifications |
Market Size Value In 2022 |
USD 5.39 Bn |
Revenue Forecast In 2031 |
USD 82.85 Bn |
Growth Rate CAGR |
CAGR of 35.6 % from 2023 to 2031 |
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
Historic Year |
2019 to 2022 |
Forecast Year |
2023-2031 |
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
Segments Covered |
By Indication, By Route of Administration, By End-users |
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
Competitive Landscape |
Lonza, Roche's, Creative Biolabs, AbbVie, Amgen, Janssen, Johnson & Johnson, IQVIA, WuXi Biologics, Sino Biological Inc., and Others. |
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |